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In this paper we bring together ethnographic research carried out during two clinical prevention trials to explore
identities, relations and political imaginations that were brought to life by these different technologies. We high-
light the ways in which critical anthropological engagement in clinical trials can help us radically reconsider the
parameters and standards of medical research. In the paper we analyse the very different circumstances that
made these two trials possible, highlighting the different temporalities and politics of HIV and Ebola as epidemics.
We then describe four themes revealed by ethnographic research with participants and their communities but
mediated by the specific sociopolitical contexts in which the trials were taking place. In both countries we found
materiality and notions of exchange to be important to participants’ understanding of the value of medical re-
search and their role within it. These dynamics were governed through social relations and moral economies
that also underpinned challenges to Western notions of research ethics. The clinical trials offered a language
to express both disaffection and disillusionment with the political status quo (often through rumours and anx-
ieties) while at the same time setting the foundations for alternative visions of citizenship. Attached to these
were expressions of ‘uncertainty and hope’ steeped in locally distinctive notions of destiny and expectations of
the future.
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Background
Since the 1990s there has been an expansion of clinical trials
in resource-poor contexts in response to emergent disease epi-
demics such as HIV and Ebola.1–6 Setting-up clinical trials in
such contexts raises political economic and social justice ques-
tions.3,7–9 In particular, the focus on participant rights, especially
through narrow framings of informed consent and researcher
and community relationships, does not take into account broader
issues of inequities in wealth and in health status and healthcare
resources.3,7,10
Drawing on ethnographic research we conducted during
two clinical trials (MDP 301 and EBOVAC-Salone), established a
decade apart, across the African continent (Tanzania and Sierra
Leone) and during two different epidemics (HIV and Ebola), we
highlight the effect of global and local power dynamics and
everyday encounters with biomedicine on the imaginaries of
trial participants and their communities. Anthropological engage-
ment with clinical trials provides a critical lens with which to ex-
amine the moral and ethical consequences that emerge from
the conduct of clinical trials as well as to explore the social, po-
litical, cultural and economic dimensions that influence clinical
trial participation and longer term legacies of clinical trials on
communities.
Anthropological reflections show that technologies are not
simply a collection of material objects that exist in isolation
from social practice, but are integral to social life and social
meaning.11,12 Microbicide gels are a technology of health, inti-
macy, pleasure and reproduction, as well as medicalisation and
the control of sex.11,13,14 They represent biopower, which de-
notes power over life, on one hand maximising the forces of the
body and on the other a focus on regulation and control of the
body.13,15,16 Vaccine development as part of a system of knowl-
edge and strategies in the eighteenth century to proliferate life
and avoid death made the possibility of living a norm rather than
a remote possibility.17 As a biotechnology they enable control
over, and positive transformation of human life, but have also
been described as a means of control of populations when vac-
cine programmes are mandatory.18 This notion of biopower may
be limited in vaccine trials where individuals make decisions to
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participate and be vaccinated. In addition, analyses of biopower
for vaccine trials ignore agency, ‘self-worry and its modes of ex-
pression’.19 Instead, we argue that biomedical technologies can
transform power and open up choices and possibilities.20 Building
on existing anthropological studies on clinical trials5,7,21–24 in this
paper, we propose a comparative approach that allows us to ex-
plore common themes in the social meaning of medical research
while also showing how these are highly specific to the context,
the epidemic and the trial in their manifestation. In our conclu-
sions we reflect on the implications of this comparative approach
for the integration of anthropological perspectives in the conduct
of clinical trials.
Situating epidemics in the political context of
Tanzania and Sierra Leone
Postcolonial Tanzania and the HIV epidemic
In 1983, the first cases of AIDS were reported in Tanzania. Over
the next 10 y cases continued to rise rapidly, reaching a peak
in the mid-1990s. By this time the epidemic had spread from
urban to rural areas.25 The epidemic coincided with an era of
massive social change and the adoption of a neoliberal agenda
by the government. Under the Arusha Declaration (Ujamaa) the
first president Nyerere had promised a decentralised government
and a programme of rural development. With demands for re-
forms of the structural adjustment programme (SAP) required by
the International Monetary Fund, the second president Mwinyi
abandoned Ujamaa and conducted amajor reform of health pol-
icy.26,27 This neoliberal shift in Tanzania created a withdrawal of
the state and a growing focus on individual choice.28 The commit-
ment to SAPs saw a sharp decline in spending on healthcare with
an immediate effect on the ability of the state to provide free and
quality health and welfare services.29 In response to these crises,
the international donor community and local non-governmental
organisations (NGOs) stepped in to provide some of the health
and welfare previously provided by the state, leading to a rapid
growth of the NGO sector. By the mid-2000s,1.6 million people
were living with HIV, the majority of whom were women.30 In
Tanzania, women were disadvantaged in relation to men in ac-
cess to education, employment and land and property owner-
ship,31,32 and this, as well as biological susceptibility, put them at
greater risk of HIV, especially thoseworking in social venues (such
as bars), where sexual transactions were common.33 With the re-
duction of government healthcare provision, HIV treatment was
only available at NGOs or private health clinics when the trial was
set up.
Postconflict Sierra Leone and the Ebola epidemic
A decade later, an outbreak of Ebola in West Africa captured
the international imagination. Sierra Leone was among the worst
affected countries, with >14 000 cases reported from 2014 to
2016.34 Initial assessments of the epidemic focused on commu-
nity resistance, bushmeat consumption and traditional practices,
however, social scientists identified structural roots.35–37 Ebola
was a disaster waiting to happen, the culmination of a particu-
lar historical trajectory steeped in the dynamics of an extractive
international political economy.38 From its key position in the At-
lantic slave trade, then a swift transition from abolitionist utopia
to British colony, Sierra Leone’s economy was designed in aid
of international capital. Rapid electoral decolonisation and the
legacy of indirect rule in the rural hinterland created significant
political challenges for independence in 1961. Colonisers left be-
hind a state with little power and legitimacy among the popu-
lation.39,40 Following independence, the establishment of a one-
party state coincided with a fall in global commodity prices and
the introduction of extensive SAPs, including the privatisation of
health services. These factors led to the exclusion of a large ma-
jority of the population from formal employment, education and
healthcare. These trends contributed to the eruption of a civil war
that lasted from 1991 to 2002. The war further dilapidated public
resources and physical infrastructure.
This legacy, combined with the postwar financing of health
services through a patchwork of internationally funded ‘vertical’
programmes, made it extremely challenging to respond to the
Ebola outbreak.38 As the virus spread, healthcare workers found
themselves ‘confronting Ebola with bare hands’.41 Meanwhile,
citizens’ relations to the national and international institutions
that were supposed to support them during the epidemic had
been eroded by a long history of extraction and neglect.42 Over
the course of the epidemic, various interventions, including ex-
tensive community engagement efforts supported by anthropo-
logical research, worked towards building confidence among af-
fected communities.43–46 It was against this backdrop, in 2015,
as the epidemic was beginning to wane, that the Ebola vaccine
trials arrived in Sierra Leone.
Methodology: anthropological engagement
with clinical trials
Microbicides trial in Tanzania (2005 to 2009)
In the early 2000s, in response to the growing epidemic among
women in Africa, there was an international effort to develop mi-
crobicide gels, substances which could be used by women, se-
cretly if need be, to protect themselves against HIV infection
through vaginal sex. The Microbicides Development Programme
(MDP) conducted a phase III, randomised, double-blind, placebo-
controlled trial in South Africa, Tanzania, Uganda and Zambia
to test the efficacy of microbicide gel.47 In Tanzania, a feasi-
bility study found that women working in social venues (bars,
restaurants; i.e. local places selling food and alcohol) had a higher
prevalence of HIV than the general population and were thus re-
cruited to participate in the trial. The income from working in so-
cial venues was under the minimum wage of US$65 per month
at the time of the study and many women supplemented their
income with transactional relationships at these venues.14 The
trial included a community liaison team and a social science
team. The community liaison team conducted regular partici-
patory dialogue meetings with participant representatives quar-
terly as well as bi-annual meetings with a stakeholder advisory
group.48,49 During the trial SL conducted 4 y of longitudinal re-
search with a team of four local research assistants to under-
stand women’s participation in the trial and community per-
ceptions of the trial within the specific historical, political and
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economic context of Mwanza City. Longitudinal data collection
involved ethnographic observations at trial clinics, social venues
and community engagement meetings, 99 in-depth interviews
with trial participants at 3 time points and 14 focus group discus-
sions.
Ebola vaccine trial in Sierra Leone (2015 to date)
The declaration of a Public Health Emergency of International
Concern in August 2014, Kelly argues, achieved an ‘epistemic
shift’ in the imagination of the West African Ebola outbreak.
Similarly, the release of models that foreshadowed exponential
growth in the epidemic underpinned moral arguments for the
international community to act, especially in vaccine develop-
ment. The ‘sense of urgency that the models conveyed trans-
formed Ebola’s value as an object of, and a resource for, global
investment’ and the ‘moral outrage and collective responsibility
unleashed by this charismatic reworking of the outbreak set the
stage for the significance of Ebola vaccines in the response’.5 Vac-
cines were expected to make up for the lost time preventing the
epidemic as it spread across West Africa. The first Ebola vaccine
trials in the context of an emergency generated heated debates
in the scientific community, including whether it was ethical to
randomise and what alternative trial designs could be identified
to fulfil evidentiary requirements while protecting the rights of
participants. Not least due to the enormous challenge of setting
up a vaccine trial at emergency speed, and given that the epi-
demic began to slow down in early 2015, testing for efficacy be-
came impossible in most situations and the trials in Sierra Leone
focused on testing for immunogenicity.
The EBOVAC-Salone trial50 was established in Sierra
Leone’s Kambia district in the spring of 2015 and tested the
Ad26.ZEBOV/MVA-BN-Filo prime-boost Ebola vaccines. At this
time the setting up of the trial coincided with the military-led
Operation Northern Push, an effort to suppress a flare up of
cases in the district, one of the final hotspots in the country.51
In October, a community lottery was held in the Paramount
Chief’s court to decide which households would be invited to
volunteer and a few weeks later the first participants were
recruited. Drawing on lessons learned from the social science
in Tanzania, SL and LE established a social science research
programme to explore experiences of the Ebola outbreak and
perceptions of the trial, contextualising these with historical,
social, economic and political factors.52 LE led the social science
with a team of five local research assistants. Data collection
methods included ethnographic observations in the trial clinics,
within the community and community engagement meetings,
22 in-depth interviews with trial participants at 2 time points,
4 life narrative interviews with trial participants, 7 focus group
discussions with trial participants and community members, as
well as 30 key informant interviews.
Drawing on the experience of theMDP trial offered insights into
how to navigate the role of social scientists in medical research,
at once supporting the conduct of the trial by translating con-
textual observations into operationalisable findings and studying
the trial itself as a social practice. We adapted research proto-
cols, designs and methodologies such as participatory rumour-
tracking activities in focus group discussions from the work that
was carried out in Tanzania. For both case studies, datawere tran-
scribed and translated to English and analysed using NVIVO soft-
ware (QSR International 1999).53 Themeswere developed as they
emerged from the analysis. Comparative analysis was conducted
through iterative discussions between LE and SL to identify com-
mon themes and context-specific differences.
Themes
Materiality and exchange
In Tanzania, the trial provided women with the opportunity to
access free, high quality sexual and reproductive care and a fi-
nancial reimbursement of US$4 for each clinic visit. While gov-
ernment sexual and reproductive health services are supposed
to be free, women are often required to pay for medication, thus
the free services represented a value.24 However, for the women
who participated, knowledgewas as vital asmateriality, acting as
an important resource to address uncertainty about their health,
the quality of healthcare, their relationships with men and, in
particular, about the HIV epidemic. When asked why they had
participated, most women said ‘Kujua afya yangu’ (To know my
health), suggesting that knowing about health is to be certain
about health. The word ‘afya’ also translates to the broader con-
cept of well-being, and knowledge of their HIV status was related
to well-being or wholeness (uzima). ‘Knowing’ was also a mo-
tive to find out if the gel worked. Their trust in the knowledge
they acquired was related to the trial’s connections to global ac-
tors. As others have noted with regard to participating in a clinical
trial, with its global linkages ‘in part substitutes for these other,
unreachable or ineffective forms of citizenship or belonging’ [p.
89],54 in this way the trial created an enclave of knowledgeable
citizens in the context of decaying government health services.28
In the EBOVAC-Salone trial, notions of material exchange and
the social expectations imbued in them, were manifested in dif-
ferent ways in participants’ reflections on their relationships with
the clinic and its staff. Participants spoke of the blood-taking, in
the midst of mistrust and fears, as a sacrifice. This was accom-
panied by expectations of exchange, or material recognition of
this sacrifice, such as in requests for the trial to provide food after
blood-giving. Longer term expectationswere expressed in the be-
lief that ‘there must be something else coming’ or that EBOVAC-
Salone surely had ‘some package [of benefits] for participants at
the end of the project’ despite an understanding of the partici-
pant information.55–57 These expectations reflect the broader dy-
namics of Sierra Leone’s political economy, where sacrificing or
‘suffering for’ more powerful others can be a pathway to recog-
nition and ‘rewards’, even if these are not explicitly promised.58
Social relations and moral economy
In the MDP trial, decisions to participate were influenced, but
not determined, by relationswithmen.59,60 Women’s experiences
of the gel were articulated through their own broader concerns
with sexuality, especially respect and equality in sexual matters.
While the use of the gel did not challenge surrounding moral dis-
courses of promiscuity andmale control, it contributed to ideas of
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equality and respect, and to some extent agency, by enabling
communication about sexualmatters with intimate partners and
notions that women’s control of sexual pleasure and risk were
possible.61,62 Although overtly naming a technology as empower-
ing does not ensure that this will be the case, the women drew on
ideas of empowerment, which were transferred from global fem-
inist activists, through the practices and meanings implicit in the
trial.63 Where condoms remained associated with promiscuity,
distrust and immoral behavior,64 the gel enhanced both intimacy
and trust between women and their partners, as well as sexual
desire, pleasure and cleanliness.62,65 While these positive aspects
were unexpected, the idea that the technology could address
women’s sexual oppression and gender inequalities resonated
with the women. In short, women’s relationships with this tech-
nology were grounded in existing habits of pragmatism: as Lock
noted, ‘If the apparent benefits outweigh the costs to themselves,
and if technology serves their own ends, then most women will
avail themselves of what is offered’ [p. 2].66
New technologies bring rumours as they are often imagined
in ways that are never considered by those who develop them.67
Thus, it was not surprising that rumours about the gel and its pur-
pose emerged. However, women defied localmoral protestations
to participate in this trial and situated themselves as ‘knowing’
in contrast to neighbours who were on the outside of the trial.
They were selective with the information they shared with their
partners or neighbours and rather focused on the benefits of the
knowledge acquired for themselves personally. Emboldened by
their new acquisition of knowledge women defied ideas about
themselves as vulnerable to, or responsible for, the HIV epidemic.
The way in which the women dealt with rumours in the commu-
nity was reflected in their ‘sense of belonging’ to the trial and
their positive engagement with the clinical trial staff. These new
social relations with trial staff created an alliance of actors ad-
dressing women’s vulnerability to HIV infection.68 While science
often makes it difficult for lay people to be involved in the devel-
opment of technologies,69 in the trial women became coproduc-
ers of knowledge.
Social relations were also built during the EBOVAC-Salone trial
and became central to its operations in ways that were not al-
ways visible. Social relations between trial staff and Kambia resi-
dents were initially fraught; by hiring staff outside the district, the
trial signified a significant influx of ‘strangers’ into town.70 This
generated tensions due to low formal employment in Kambia,
as well as the growing number of relatively well-off people who
could rent homes and stimulate the economy. This was partic-
ularly meaningful as the trial’s set-up phase coincided with the
winding down of the outbreak response, which had distorted the
local economy by bringing ‘Ebolamoney’. It had also built resent-
ment for those who were not employed by response.71 As the re-
sponse apparatus retracted, EBOVAC-Salone became the primary
employer in town.
Themoral economies generated through the arrival of the trial
were particularly pronounced for the ‘sons of the soil’, the smaller
number of staff recruited from Kambia. These staff showed par-
ticipants that people they trusted were involved, however, there
were higher expectations placed on them. This included obliga-
tions to ‘give back’, by using their salaries to build a house in town
and to participate in communal activities.
Citizenship
In the MDP trial, rumours also emerged about blood stealing.
The idiom of blood stealing is a narrative that is ever present but
is only voiced or realised in unclear or threatening social situ-
ations, and medical research conducted by Europeans has his-
torically been experienced as such.72 Blood stealing is one of
the most common rumours associated with medical research
in Africa.23,72–76 Despite these rumours, women participated in
the trial as an act of ‘biological citizenship’, where the biologi-
cal responsibilities of citizens were embodied in norms of health
and health protection.77,78 Biological citizenship is both individu-
alising and collectivising, individualised in that individuals shape
their relation with themselves to their biological existence, and
collectivised in that individuals organise themselves into specific
biomedical classifications, often with specialised medical knowl-
edge of their condition.79 This notion of individual and collective
biological responsibility was articulated by the women who pre-
sented themselves as individuals who took responsibility for their
own health by seeking quality healthcare and treatment, as well
as the possibility of personal protection from HIV, but also as part
of a collective who used their biological existence to test the mi-
crobicide gel, for the wider good of society. Citizenship was also
expressed through motives to participate. The trial was named
Mwanamke Amua kuhusu Maisha yaKO (Woman–decide about
your own life) during a consultation with women representatives.
In this agreement the intentions of the trial staff converged with
women’s aspirations for equality and control over HIV prevention
for themselves and other Tanzanian women.
The EBOVAC-Salone trial participants also expressed and per-
formed notions of citizenship.70 These included expressions of
participation as a national sacrifice, to prevent future outbreaks
in view of the crisis that had unfolded in the country. Partici-
pants’ engagements with the trial also elicited other imagina-
tions of what it ought to mean to be a citizen, as they contrasted
the healthcare provided in the trial clinics with that in the gov-
ernment hospital. The trial also entered the political imagina-
tion and longstanding negotiations about citizenship through ru-
mours and anxieties that circulated. For example, one rumour
emerged that the trial was a pretext to steal blood for foreign
use or that participants were injected with Ebola. These were in-
tertwined with anxieties about the epidemic, the role of interna-
tional actors and government collusion to ‘sell’ its citizens. These
were thusways of expressing deep-seatedmistrust and of articu-
lating perceptions of precarity and marginality as Sierra Leonean
citizens. At the same time, direct engagement with trial manage-
ment, including through the advisory modelled on the MDP trial,
created new avenues to make demands and assert participants’
rights.
Uncertainty and hope
In the MDP trial, women articulated uncertainty in everyday life
and in the precarious nature of their existence.80 They dealt with
threats and possibilities every day by drawing on strategies to
reduce the chance of negative occurrences and to increase the
possibilities of positive ones. These included seeking divine in-
tervention, being brave and seeking knowledge and technology.
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Their accounts reflected the realities of their economic vulnera-
bility, as well as threats to their physical selves from accidents,
violence and disease, especially HIV.81,82 In discussing HIV, the
women also constituted themselves as actors of illicit behaviour
or as powerless subjects of men’s illicit behaviour. They partic-
ipated in the trial to alleviate their anxiety about HIV infection,
however, the uncertainty about the gel’s effectiveness accentu-
ated this anxiety. While they understood that the gel’s effective-
ness to protect against HIV was uncertain, the gel was imbued
with hope. Specifically, they ‘hoped’ that it protected them from
HIV through its cleansing and lubricating properties.
The EBOVAC-Salone participants also articulated uncertainty
in two inter-related ways, to express concerns about the vaccine
itself and to relate their experiences of the trial to everyday expe-
rience of insecurity. Uncertainty about the vaccine was expressed
in the very meaning of a trial, and not knowing whether the vac-
cine would ‘work’ or whether it would have side effects. For some
participants the decision to take part in the trial was not out of
conviction that the trial would be safe but rather despite a per-
ception that the risk might be high. This reasoning was not ‘fa-
talistic’ but rather better understood through notions of destiny
and faith that underpin daily efforts to navigate uncertainty. The
uncertain outcome of the trial was explained by noting that ‘ev-
erything in life is a risk’.
Drawing on experiences of uncertainty and an acceptance of
destiny, participants took part in the trial with both apprehen-
sion and hope. An acceptance of risk, in other words, also opened
up the possibility that one’s destiny in the trial could be positive.
Hopes were linked to an expectation that the vaccine would work
for those who took part in trial, and the possibility that the vac-
cine would be able to cure other ills and lead to a general im-
provement in their health. These hopes were not simply miscon-
ceptions but a social resource as the trial entered participants’
longer term life trajectories and imaginations.55
Discussion
Comparative ethnographies
This paper presents a comparative approach across contexts, epi-
demics and technologies and its value lies in its ability to re-
veal the salience of history and politics in epidemic contexts,
and the role of local understandings of technologies that are
implemented to prevent the spread of disease. Exploring nar-
ratives from participants in Sierra Leone and Tanzania compar-
atively, we are able to see how biomedical technologies locate
themselves in social imageries in meaningful ways. We identify
common themes but trace them as they become enacted in
context-specific ways, with different implications for each trial.
This comparison, identifying both commonality and specificity,
allows us to suggest that these themes may be significant be-
yond the context in which we have studied them, although their
empirical manifestation will differ across communities, diseases
and particular technologies and trial designs. This approach un-
derscores the importance of engaging with the social practice of
medical research comparatively, setting out an agenda for an-
thropological contributions to the research of, and engagement
with, clinical trials across Africa and beyond.
The emergence of the HIV epidemic in Tanzania revealed the
fragility of a healthcare system unable to cope and the reliance
on international NGOs for prevention and care. The unequal ef-
fects on Tanzanian women’s education and employment follow-
ing structural adjustment exposed their vulnerabilities to HIV in-
fection, especially those working in social venues. Sierra Leone’s
Ebola emergency was different from Tanzania’s HIV crisis be-
cause of the different temporality of emergency that made the
unprecedented fast tracking of clinical research imaginable. Yet
the emergence of Ebola, and later engagements with vaccine tri-
als, also made visible the consequences of an extractive interna-
tional political economy culminating with the decimation of pub-
lic healthcare under structural adjustment.
Against this backdrop, our comparative analysis showed the
ways in which materiality and exchange are important effects
of clinical trials. Clinical trial procedures involve a complex ex-
change of blood, money, knowledge, drugs and so on between
the researchers and those participating in research.21 In addition,
clinical trials are a productive process, involving time, discomfort,
movement and risk.83 For the MDP participants, these exchanges
were articulated both in material terms, for example, of reim-
bursement and free healthcare for blood, time and discomfort,
as well as immaterial forms of knowledge exchange. EBOVAC-
Salone participants similarly focused on blood-giving as a form
of sacrifice that elicited expectations of future rewards, both ma-
terial and immaterial.
In this, social relations were key, both those that predated the
trials and made them possible and those that were generated
by the arrival of the clinical trial. The MDP trial revealed how so-
cial relations were negotiated with women’s partners, their com-
munities and the trial staff. The trial, specifically, was part of a
wider social and ideological terrain upon which women negoti-
ated gender dynamics, intimacy and sexual meanings.84 The trial
exposed the women, their partners and local communities to sci-
entific agendas that had moral underpinnings and impacted on
the way that sexuality was explored and shaped.85,86 The trial
emphasised a medicalised sexuality, separated from the realities
of everyday life.87 While science frames sexual acts in seemingly
amoral biological terms, scientific discourses within the trial had
a set of moral assumptions about women’s sexual lives, specifi-
cally around transactional sex. The trial became a place in which
sexuality was negotiated and certain sexual practices such as sex
without condoms were discouraged.87 The trial also advertently
or inadvertently shaped women’s sexuality in creative and pos-
itive ways, through creating new ideas about equality, pleasure
and desire and control over HIV.
The EBOVAC-Salone trial generated different kinds of relations,
social imageries and moral economies. As a different technol-
ogy, the vaccine did not centre on sexuality (although this did
arise in relation to contraception requirements), but rather on
the meaning of community. Tensions about the boundaries of
community and the arrival of ‘strangers’ as trial staff, the political
economy of work and of ‘Ebola money’ were countered by the
expectations placed on ‘sons of the soil’. These discussions cre-
ated opportunities to talk about community development and to
hold international and state interventions accountable. We ex-
plored these tensions and articulations as they emerged through
narratives of citizenship and belonging. These narratives also ap-
peared through rumours and anxieties that represent local
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commentaries to express concern and interpretations of
ethics.23,72–74,88 The political dimensions of rumours and anx-
ieties around the two trials offered a language to express
both disaffection and disillusionment with political life through
rumours and anxieties, while at the same time setting the
foundations for emancipatory visions of citizenship and deliber-
ation.70
Clinical trial participation and future orientation
Where inequality and poverty dominate, concerns about health
and the experience of biomedical technologies ‘seem more
about the here and now of medicine than its future possibilities’
[p. 456].88 Indeed, our research shows that participants’ experi-
ences materialise through specific political economies and gen-
erate social relations and identities in the present. Our research
also shows that, just as these biomedical technologies facilitate
a particular kind of scientific imagination aboutmanaging the fu-
ture, the gel and the vaccine also entered into trial participants’
hopes, anticipations and future-oriented imaginaries.
Both trials created platforms to discuss the uncertainty of the
present. Rather than centre these narratives on misfortunes, trial
participants reflected on risk as an openness to possibility.89 In
contrast to the idea of risk that all future and unexpected events
are necessarily negative, uncertainty suggests that future out-
comes may also be creative and productive.90,91 For Ådahl, ‘un-
predictability or contingency is something that actors engage
within their everyday life as an enabling aspect of contemporary
social experience, leading to creative and varied actions to come
to termswith the situation’ [pp. 60–1].92 Acting subjunctivelywith
the knowledge that to live is to take risks was accompanied in
both sites by a conviction that one’s trajectory is determined by
powers bigger than ourselves.89 Rather than fatalism, this kind
of reasoning is best understood through anthropological explo-
rations of ‘destiny’ as a way to make sense of how ‘people imag-
ine and reckon with determining powers’.93 An anthropology of
destiny allows us to consider how to explore the intersection of
a sense of one’s ‘capacity, and responsibility to act in their lives’
and ‘worldly and transcendental powers’ [p. 91]. The result is of-
ten amalleable fixity, a sense that onemakes decisions and nav-
igates terrains that are at least partly preordained. Rather than
relinquishing agency to a prewritten fate, then, ideas about des-
tiny underwrite and make it possible to coexist with a feeling of
uncertainty.
A key resource for all of the participants in navigating the
tension between uncertainty and destiny was hope. Hope was
imbued in the technologies themselves, through narratives of
protection, well-being and expectations of individual and com-
munal betterment that the trials’ presence was seen to symbol-
ise.94,95 Engagements with biomedicine, in other words, gener-
ated new avenues for imagining the future. Although expressed
in more open-ended and uncertain terms than the ‘biomedical
triumphalism’ of technologies like vaccines, these anticipations
were no less hopeful.5
Conclusions
Our comparative ethnographies allow us to highlight the contri-
butions of critical anthropological engagement in clinical trials,
taking into account global and local power dynamics while giving
space to the voices, imaginaries, hopes and anticipations of trial
participants and their communities. These narratives are often
hidden by the clinical imagination of the research encounter en-
capsulated in trial protocols and informed consent forms. A com-
parative approach that highlights both what is common in the
social experience of medical research and how these commonal-
ities are actualised in context-specific ways offers two key contri-
butions. First, it posits a thematic agenda for future research that
explores notions of exchange, social relations, political imageries
and notions of destiny as domains of a comparative anthropology
of medical research across different contexts, technologies, trial
designs and diseases. It will be particularly important to develop
this comparative agenda to explore how these themes might
take on newmeaning among participants in therapeutic or inter-
vention trials. Second, it highlights how anthropology can support
the design and conduct of clinical trials, expanding our under-
standing of the social value of clinical research96–98 and show-
ing that trial practices, protocols and technologies do not exist
independently of participants’ broader social experiences. Taking
participants’ life worlds and deliberations as starting points for
research design, rather than as parallel conversations or simply
as barriers to ‘acceptability’, can begin to radically reconsider the
parameters and standards of medical research.
Authors’ contributions: Both SL and LE conducted primary research for
the findings for the paper. Both SL and LE contributed to the final version
of the manuscript.
Funding: This research has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant agreement No
115854. This Joint Undertaking receives support from the European
Union’s Horizon 2020 research and innovation programme and the Eu-
ropean Federation of Pharmaceutical Industries and Association and the
UK Department for International Development through the Medical Re-
search Council [grant number G0100137].
Competing interests: None declared.
Ethical approval: Ethical approval for the trials and the anthropologi-
cal studies was gained from the London School of Hygiene and Tropi-
cal Medicine (LSHTM) Ethics Committee, the Tanzanian Medical Research
Coordinating Committee (MRCC) and the Sierra Leone Ethics and Review
Committee.
References
1 Booth KM. A magic bullet for the “African” mother? Neo-imperial
reproductive futurism and the pharmaceutical “solution” to the
HIV/AIDS crisis. Soc Polit Int Stud Gender State Soc. 2010;17:349.
2 Adams V, Miller S, Craig S, et al. The challenge of cross-cultural clini-
cal trials research: case report from the Tibetan autonomous region,
People’s Republic of China. 2005;19:267–89.
3 Benatar SR, Singer PA. Responsibilities in international research: a new
look revisited. J Med Ethics. 2010;36:194.
4 Petryna A. Clinical trials offshored: On private sector science and pub-
lic health. Biosocieties. 2007;2:21–40.
580
International Health
5 Kelly AH. Ebola vaccines, evidentiary charisma and the rise of global
health emergency research. Econ Soc. 2018;47:135–61.
6 FolayanMO, Yakubu A, Haire B, et al. Ebola vaccine development plan:
Ethics, concerns and proposed measures. BMC Med Ethics. 2016;17:
1–8.
7 Molyneux S, Geissler PW. Ethics and the ethnography of medical re-
search in Africa. Soc Sci Med. 2008;67:685–95.
8 Kapiga S, Kelly C, Weiss S, et al. Risk factors for incidence of sexually
transmitted infections among women in South Africa, Tanzania, and
Zambia: results from HPTN 055 study. Sex Transm Dis. 2009;36:199–
206.
9 Kelly A, Center BT, Wingard BCLM. Ebola, Running Ahead. 2015;(5).
https://limn.it/articles/ebola-running-ahead/.
10 Wight D. Most of our social scientists are not institution based…they
are there for hire-Research consultancies and social science capacity
for health research in East Africa. Soc Sci Med. 2008;66:110–6.
11 Gordo-López ÁJ, Cleminson R. Techno-Sexual Landscapes: Changing
Relations between Technology and Sexuality. Free Association Books;
2004.
12 Johnson D. Sorting out the question of feminist technology. In: Layne
L, Vostral S, Boyer K (eds). Feminist Technology. Chicago, IL: University
of Illinois Press, 2010; p. 36–54.
13 Foucault M, Hurley R. The History of Sexuality: The Will to Knowledge.
London, UK: Penguin; 1998.
14 Lees S. Emergent HIV technology: urban Tanzanian women’s narra-
tives of medical research, microbicides and sexuality. Cult Health Sex.
2014;17:1–16.
15 Marsland R, Prince R. What is life worth? exploring biomedical in-
terventions, survival, and the politics of life. Med Anthropol Q.
2012;26:453–69.
16 Rabinow P, Rose N. Biopower today. Biosocieties. 2006;1:195–217.
17 Engels KS. Biopower, normalization, and HPV: A Foucauldian analysis
of the HPV vaccine controversy. J Med Humanit. 2016;37:299–312.
18 Foucault M. Society Must Be Defended; Lectures at the Collège de
France, 1975-1976.Bertani M, Fontana A, Ewald F, et al. (eds). New
York, NY: Picador; 2003.
19 Leach M, Fairhead J. Vaccine Anxieties: Global Science, Child Health
and Society. Earthscan; 2007.
20 Rose N. The Politics of Life Itself: Biomedicine, Power, and Subjectivity
in the Twenty-First Century. Princeton, USA: PrincetonUniversity Press;
2008.
21 Geissler PW, Kelly A, Imoukhuede B, et al. “He is now like a brother,
I can even give him some blood’-Relational ethics and material ex-
changes in a malaria vaccine” - relational ethics and material ex-
changes in a malaria vaccine “trial community” in The Gambia. Soc
Sci Med. 2008;67:696–707.
22 Brown H, Kelly AH, Marí Sáez A, et al. Extending the “social”: anthro-
pological contributions to the study of viral haemorrhagic fevers. PLoS
Negl Trop Dis. 2015;9:2–5.
23 Geissler PW, Pool R. Editorial: Popular concerns about medical re-
search projects in sub-Saharan Africa - a critical voice in debates
about medical research ethics. Trop Med Int Heal. 2006;11:975–82.
24 Geissler PW. Transport to Where? J Cult Econ. 2011;4:45–64.
25 Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission
(ZAC), National Bureau of Statistics (NBS), Office of the Chief Gov-
ernment Statistician (OCGS), and ICF International 2013. Tanzania
HIV/AIDS and Malaria Indicator Survey 2011-12. Dar es Salaam, Tan-
zania: TACAIDS, ZAC, NBS, OCGS, and ICF International.
26 Lugalla J. The impact of structural adjustment policies onwomen and
children’s health in Tanzania. In: Heggenhougen K, Lugalla J (eds).
Social Change and Health in Tanzania. Dar es Salaam: Dar es Salaam
University Press, 2005; p. 243–79.
27 Kopoka P. Women, Poverty and HIV/AIDS in Africa: The fate of young
women working as maids in Tanzania. In: Heggenhougen K, Lugalla
J (eds). Social Change and Health in Tanzania. Dar es Salaam: Dar es
Salaam University Press, 2005; p. 257–79.
28 Ferguson J. Global Shadows: Africa in the Neoliberal World Order.
Durham and London: Duke University Press; 2006.
29 Turshen M. Privatizing Health Services in Africa. Rutgers University
Press; 1999.
30 Steinbrook R. The AIDS Epidemic in 2004. N Engl J Med.
2004;351:115–7.
31 Ellis A, Blackden M, Cutura J, et al. Gender and Economic Growth in
Tanzania: Creating Opportunities for Women. The International Bank
for Reconstruction and Development/The World Bank; 2007.
32 Meena R. Women Participation in Positions of Power and Influence in
Tanzania. Research and Education for Democracy Conference; 2009.
33 Vallely A, Hambleton I, Kasindi S, et al. Are women who work in bars,
guesthouses and similar facilities a suitable study population for vagi-
nal microbicide trials in Africa? PLoS One. 2010;5:e10661.
34 Centers for Disease Control and Prevention (CDC). 2014 Ebola Out-
break in West Africa - Case Counts. 2016.
35 Wilkinson A, Leach M. Briefing: Ebola-myths, realities, and structural
violence. Afr Aff. 2015;114:136–48.
36 McGovern M. Bushmeat and the politics of disgust. Hotspots Cult An-
thropol. Field Sites–Hot Spots, Cultural Anthropology Online, 2014.
www.culanth.org.
37 Abdullah I, Rashid IOD. Understanding West Africa’s Ebola Epidemic:
Towards a Political Economy. Chicago, IL: University of Chicago Press;
2017.
38 Benton A, Dionne KY. International Political Economy and the 2014
West African Ebola Outbreak. Afr Stud Rev. 2015;58:223–36.
39 Harris D. Sierra Leone: A Political History. London, UK: Hurst & Co.;
2013.
40 Kandeh JD. Sierra Leone: contradictory class functionality of the ’soft’
state. Rev Afr Polit Econ. 1992:30–43.
41 Abdullah I, Kamara AB. Confronting Ebola with bare hands: Sierra
Leone’s health sector on the eve of the Ebola epidemic. In: Abdul-
lah I, Rashid IOD (eds). Understanding West Africa’s Ebola Epidemic:
Towards a Political Economy. Chicago, IL: University of Chicago Press;
2017.
42 Enria L. “You think this is an Ebola Office?” Rebuilding trust in the




43 Bedson J, JallohMF, Pedi D, et al. Community engagement during out-
break response: standards, approaches, and lessons from the 2014-
2016 Ebola outbreak in Sierra Leone. bioRxiv. 2019:661959.
44 Wilkinson A, Parker M, Martineau F, et al. Engaging “communities”:
anthropological insights from theWest African Ebola epidemic. Philos
Trans R Soc Lond B Biol Sci. 2017;372:20160305.
45 Lees S, Palmer J, Procureur F, et al. Contested legitimacy for anthro-
pologists involved in medical humanitarian action: experiences from
the 2014-2016 West Africa Ebola epidemic. Anthropol Med. 2020:
1–19.
581
S. Lees and L. Enria
46 RyanMJ, Giles-Vernick T, Graham JE. Technologies of trust in epidemic
response: openness, reflexivity and accountability during the 2014-
2016 Ebola outbreak in West Africa. BMJ Glob Heal. 2019;4:e001272.
47 Nunn A, McCormack S, Crook AM, et al. Microbicides Development Pro-
gramme: design of a phase III trial to measure the efficacy of the
vaginalmicrobicide PRO 2000/5 for HIV prevention. Trials. 2009;10:99.
48 Shagi C, Vallely A, Kasindi S, et al. A model for community represen-
tation and participation in HIV prevention trials among women who
engage in transactional sex in Africa. AIDS Care. 2008;20:1039–49.
49 Vallely A, Shagi C, Kashindi S, et al. The benefits of participatory
methodologies to develop effective community dialogue in the con-
text of a microbicide trial feasibility study in Mwanza, Tanzania. BMC
Public Health. 2007;7:133.
50 Mooney T, Smout E, Leigh B, et al. EBOVAC-Salone: lessons learned
from implementing an Ebola vaccine trial in an Ebola-affected coun-
try. Clin Trials. 2018;15:436–43.
51 Enria L. The Ebola crisis in Sierra Leone: mediating contain-
ment and engagement in humanitarian emergencies. Dev Change.
2019;50(6):1602–23.
52 Enria L, Lees S, Smout E, et al. Power, fairness and trust: understand-
ing and engaging with vaccine trial participants and communities in
the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC
Public Health. 2016;16:1140.
53 International (1999) NVivo Qualitative Data Analysis Software
[Software]. Available from: https://qsrinternational.com/nvivo/nvivo-
products/.
54 Leach M, Fairhead J. Being “with Medical Research Council”: Infant
Care and the Social Meanings of Cohort Membership in Gambia’s
Plural Therapeutic Landscapes. In: Geissler PW, Molyneux C (eds).
Evidence, Ethos and Ethnography: The Anthropology and History of
Medical Research in Africa. New York/Oxford: Berghahn Books, 2011;
p. 77–98.
55 Tengbeh AF, Enria L, Smout E, et al. “We are the heroes because
we are ready to die for this country”: Participants’ decision-making
and grounded ethics in an Ebola vaccine clinical trial. Soc Sci Med.
2018;203:35–42.
56 Jansen LA,MahadevanD, AppelbaumPS, et al. Dispositional optimism
and therapeutic expectations in early-phase oncology trials. Cancer.
2016;122(8):1238–46.
57 Horng S, Grady C. Misunderstanding in clinical research: Distinguishing
therapeuticmisconception, therapeuticmisestimation, & therapeutic
optimism. IRB Ethics Hum Res. 2003;25(1):11–6.
58 Enria L. The Politics of Work in a Post-Conflict State: Youth, Labour &
Violence in Sierra Leone. James Currey Publishers; 2018.
59 Samuelsen H, Steffen V. The relevance of Foucault and Bour-
dieu for medical anthropology: Exploring new sites. Anthropol Med.
2004;11:3–10.
60 Hoeyer K, Lynoe N. Motivating donors to genetic research? Anthropo-
logical reasons to rethink the role of informed consent. Med Heal Care
Philos. 2006;9:13–23.
61 Gafos M. Microbicides, sexuality and sexual health in KwaZulu-Natal,
South Africa (Unpublished Doctoral thesis, City University London);
2013.
62 Montgomery CM, Lees S, Stadler J, et al. The role of partnership dy-
namics in determining the acceptability of condoms and microbi-
cides. AIDS Care. 2008;20:733–40.
63 Layne L. Introduction. In: Layne L, Vostral S, Boyer K (eds). Fem-
inist Technology. Chicago, IL: University of Illinois Press, 2010;
p. 1–35.
64 Dilger H. Sexuality, AIDS, and the lures of modernity: reflexivity and
morality among young people in rural Tanzania. Med Anthropol.
2003;22:23–52.
65 Stadler J, Saethre E. Blockage and flow: intimate experiences of con-
doms andmicrobicides in a South African clinical trial. Cult Health Sex.
2011;13:31–44.
66 Lock M, Kaufert P. Introduction. In: Lock MM, Kaufert PA (eds). Prag-
matic Women and Body Politics. Cambridge University Press, 1998; p.
1–27.
67 Stadler J, Saethre E. Blockage and flow: intimate experiences of con-
doms and microbicides in a South African clinical trial. Cult Heal Sex.
2011;13:31–44.
68 Leach M, Scoones I, Wynne B. Commentary. In: Leach M, Scoones I,
Wynne B (eds). Science and Citizens: Globalization and the Challenge
of Engagement. London, UK: Zed Books, 2005; p. 97–112.
69 Sclove RE. Sociable Technology and Democracy. New York: The Guil-
ford Press; 2005.
70 Enria L, Lees S. Citizens, dependents, sons of the soil: defining
political subjectivities through encounters with biomedicine during
the Ebola epidemic in Sierra Leone. Med Anthropol Theory. 2018;5:
30–55.
71 Shepler S. “We Know Who Is Eating the Ebola Money”: Political ef-
fects of perceived corruption in the Ebola response. Anthropol Q.
2017;90:457–80.
72 Geissler PW. “Kachinja are coming!”: Encounters around medical re-
search work in a Kenyan village. Africa. 2005;75:173–202.
73 Fairhead J, Leach M, Small N. Where techno-science meets poverty:
Medical research and the economy of blood in The Gambia, West
Africa. Soc Sci Med. 2006;63:1109–20.
74 Molyneux C, Wassenaar D, Peshu N, et al. “Even if they ask you to
stand by a tree all day, youwill have to do it (laughter)…!”: community
voices on the notion and practice of informed consent for biomedical
research in developing countries. Soc Sci Med. 2005;61:443–54.
75 White L. Speakingwith Vampires: Rumor andHistory in Colonial Africa.
London, UK: University of California Press; 2000.
76 Weiss B. Electric vampires: Haya rumours of the commodified body.
In: Lambek M, Strathern A (eds). Bodies and Persons: Comparative
Perspectives from Africa and Melanesia. Cambridge, UK: Cambridge
University Press, 1998; p. 172–96.
77 Rose N, Novas C. Biological citizenship. In: Ong A, Collier SJ (eds).
Global Assemblages: Technology, Politics, and Ethics as Anthropolog-
ical Problems. London, UK: John Wiley & Sons, 2008; p. 438–63.
78 Petryna A. Biological citizenship: The science and politics of
Chernobyl-exposed populations. Osiris. 2004;19:250–65.
79 Rose N, Novas C. Biological citizenship. In: Ong A, Collier SJ (eds).
Global assemblages: Technology, politics and ethics as anthropolog-
ical problems. Malden, MA: Blackwell Publishing, 2005; p. 439–63.
80 Jackson M. Paths Toward a Clearing: Radical Empiricism and Ethno-
graphic Inquiry. Indiana University Press; 1989.
81 Boniface R, Museru L, Kiloloma O, Munthali V. Factors associated with
road traffic injuries in Tanzania. Pan Afr Med J. 2016;23:46.
82 Tanzania National Bureau of Statistics.WomenMen in Tanzania: Facts
and Figures 2017.Tanzania: National Bureau of Statistics (NBS); 2017.
83 Geissler PW. ‘Transport To Where?’ J Cult Econ. 2011;4:45–64.
84 Hirsch J, Wardlow H, Smith D, et al. The Secret: Love, Marriage, and
HIV. Nashville, TN: Vanderbilt University Press; 2009.
85 Pigg S, Adams V. Introduction: The Moral Object of Sex. In: Adams V,
Pigg S (eds). Sex in Development: Science, Sexuality, and Morality in
582
International Health
Global Perspective. Durham& London: Duke University Press, 2005; p.
1–38.
86 Nguyen V. Uses and Pleasures: Sexual modernity, HIV/AIDS, and con-
fessional technologies in a West African metropolosis. In: Adams V,
Pigg S (eds). Sex in Development: Science, Sexuality, and Morality in
Global Perspective. Durham& London: Duke University Press, 2005; p.
245–68.
87 Adams V, Pigg S. Sex in Development: Science, Sexuality, and Moral-
ity in Global Perspective. Durham & London: Duke University Press;
2005.
88 Molyneux C, Peshu N, Marsh K. Understanding of informed consent in
a low-income setting: three case studies from the Kenyan Coast. Soc
Sci Med. 2004;59:2547–59.
89 Whyte S. Uncertain Undertakings: Practicing health care in the
subjunctive mood. In: Jenkins R, Jessen H, Steffen V (eds). Man-
aging Uncertainty: Ethnographic Studies of Illness, Risk and the
Struggle for Control. Copenhagen, Denmark: Museum Tusculanum,
2005; p. 245–64.
90 Geissler PW, Prince RJ. The Land Is Dying: Contingency, Creativity and
Conflict in Western Kenya. Berghahn Books; 2009.
91 Malaby TM. Odds and ends: risk, mortality, and the politics of contin-
gency. Cult Med Psychiatry. 2002;26:283–312.
92 Ådahl S. Good live, hidden miseries: an ethnography of uncertainty in
a Finnish village. Department of Sociology, Research Reports no. 250,
Helsinki: Helsingin yliopiston sosiologian laitoksen tutkimuksia; 2007.
93 Elliot A, Menin L. For an anthropology of destiny. HAU J Ethnogr
Theory. 2018;8:292–9.
94 Davis M, Squire C. HIV technologies. In: Davis M, Squire C (eds). HIV
Treatment and Prevention Technologies in International Perspective.
Palgrave Macmillan, 2010; p. 1–17.
95 Rosengarten M, Michael M. The performative function of expectations
in translating treatment to prevention: The case of HIV pre-exposure
prophylaxis, or PrEP. Soc Sci Med. 2009;69:1049–55.
96 Kelly A. Remember Bambali: evidence, ethics and the co-production
of truth. In: Geissler PW (ed.). Evidence, ethos and ethnography:
The anthropology and history of medical research in Africa. Oxford:
Berghahn; p. 2011:229–44.
97 Henderson GE, Rennie S, Corneli A, et al. Parallel but connected: Nu-
ances of conducting behavioral and social science research alongside
ethically challenging HIV remission trials. Contemp Clin Trials Com-
mun. 2020;19:100594.
98 Corneli A, Meagher K, Henderson G, et al. How biomedical HIV pre-
vention trials incorporate behavioral and social sciences research: A
typology of approaches. AIDS Behav. 2019;23:2146–54.
583
